

Protex Mobility, Inc.

One West Las Olas Blvd., Ste 500
Fort Lauderdale, FL. 33301

+27 79 107 0886

www.protxtm.com

exportintl@aol.com

SIC 2833

Quarterly Report

For the period ending September 30, 2024 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

8,791,221,631 as of September 30, 2024 (Current Reporting Period Date or More Recent Date)

8,791,221,631 as of December 31, 2023 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Protex Mobility- December 2010 - present
EchoMetrix- May, 2009- December, 2010
SearchHelp, Inc.- September, 2001 -May, 2009

Current State and Date of Incorporation or Registration: Delaware, 12/21/2010
Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:
N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On June 3, 2022, the Company acquired 100% of the capital stock of RSAMMD Acquisitions LLC, a Delaware company, in exchange for 100,000 shares of Series D Preferred stock and 50,000 shares of Series A Preferred stock. Combined, these shares entitle the shareholders of RSAMMD to 85% of the votes on all shareholder matters with conversion rights equal to the number of votes. Mr.Dylon Du Plooy and Dr. Ahmed Jamalooden are the principals of this entity and are the beneficial owners of the Protex controlling stock.

Address of the issuer's principal executive office:

One West Las Olas Blvd.,
Ste 500 Fort Lauderdale, FL,
33301

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Clear Trust, LLC
Phone: 813-235-4490
Email: inbox@cleartrusttransfer.com
Address: 16540 Pointe Village Dr.
Suite 205 Lutz, FL 33558

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>TXTM</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>74371E204</u>	
Par or stated value:	<u>\$0.00001</u>	
Total shares authorized:	<u>10,000,000,000</u>	<u>as of date: September 30, 2024</u>
Total shares outstanding:	<u>8,791,221,631</u>	<u>as of date: September 30, 2024</u>
Total number of shareholders of record:	<u>77</u>	<u>as of date: September 30, 2024</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Series A Convertible Preferred Stock</u>	
CUSIP (if applicable):	<u>n/a</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>100,000</u>	<u>as of date: September 30, 2024</u>
Total shares outstanding (if applicable):	<u>50,000</u>	<u>as of date: September 30, 2024</u>
Total number of shareholders of record (if applicable):	<u>2</u>	<u>as of date: September 30, 2024</u>

Exact title and class of the security:	<u>Series B Preferred Stock</u>	
CUSIP (if applicable):	<u>N/A</u>	
Par or stated value:	<u>\$0.0001</u>	
Total shares authorized:	<u>1,000,000</u>	<u>as of date: September 30, 2024</u>
Total shares outstanding (if applicable):	<u>0</u>	<u>as of date: September 30, 2024</u>

Total number of shareholders of record (if applicable): 0 as of date: September 30, 2024

Exact title and class of the security: Series C Preferred
CUSIP (if applicable): N/A
Par or stated value: \$0.001
Total shares authorized: 3,900,000 as of date: September 30, 2024
Total shares outstanding (if applicable): 2,675,000 as of date: September 30, 2024
Total number of shareholders of record (if applicable): 1 as of date: September 30, 2024

Exact title and class of the security: Series D Convertible Preferred Stock
CUSIP (if applicable): N/A
Par or stated value: \$0.001
Total shares authorized: 100,000 as of date: September 30, 2024
Total shares outstanding (if applicable): 100,000 as of date: September 30, 2024
Total number of shareholders of record (if applicable): 2 as of date: September 30, 2024

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

One for one voting on all common stock, entitled to dividends as determined by the board of directors. No Pre-emptive rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A Convertible Preferred Stock- Voting Rights- Shall be entitled to the number of votes as shall be equal to the aggregate number of shares of Common Stock into which the Series A shall be convertible. Liquidation – Holders shall be entitled to receive out of the assets of the corporation an amount equal to the Holder's pro rata share of the assets and funds of the corporation to be distributed. Conversion- Convertible into fully paid and non-assessable shares of Common Stock in aggregate equal to 20% of the post conversion number of shares of Common Stock issued and outstanding. Individual shares of Preferred Stock shall be convertible into that pro-rata number of common shares equal to .00001 X the aggregate number of shares issuable. There are no redemption rights.

Series B Preferred Stock – The holders of outstanding shares of Series B Preferred Stock shall be entitled, while shares of the Series B Preferred stock are outstanding, to cash dividends consisting in the aggregate of \$3,375,000 (the "**Special Dividend Amount**") subject to certain conditions as set forth in the certificate of designation. The holders of Series B Preferred shall also be entitled to cumulative dividends. Liquidation- The holders of Series B Preferred shall be entitled to receive, pro rata based on the number of shares of Series B Preferred Stock held, pari passu with the payment or distribution of assets of the Company to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the sum of (A) the Purchase Price plus an annualized internal rate of return of 8% for the period from the issuance date of the issued and

outstanding Series B Preferred Stock to the date when all amounts under this section are in full, and (B) an amount equal to all declared but unpaid dividends for each outstanding share of Series B Preferred Stock proportionally adjusted for recapitalizations. Conversion- shall be convertible into fully paid and non- assessable shares of Common Stock as is determined by dividing the Purchase Price by the conversion price. The initial conversion price shall be \$0.0909, which implies that each share of Series B Preferred Stock is initially convertible into Common Stock on a 1- to- 100 basis. Voting Rights- Series B Preferred shall have the right to such number of votes for each share of common stock into which such share of Series B Preferred stock may then be converted pursuant to Section 5 of the Certificate of Designation equal to fifty-one percent (51%) of the outstanding common stock on an as-converted basis, only with respect to a proposal to amend the Certificate of Incorporation to increase the number of shares of capital stock authorized thereunder. In addition, the holders of Series B preferred shall have the right to two (2) votes for each share of common stock into which such share of Series B Preferred Stock could then be converted. There are no redemption rights.

Series C Preferred- Dividends- Shall not be entitled to receive any dividends. Voting- Shall vote together with the common stock as a single class on a one hundred (100) votes per share of Series C Preferred basis. No Preemption rights. Redemption rights: The corporation shall have the right to redeem the shares of Series C Preferred at any time after the date of issuance at a per share price equal to the per share price paid for such shares. In addition, the holder of Series C Preferred may also require the corporation to redeem shares of Series C Preferred at any time after the date of issuance at per share price equal to the price paid by the holder for such shares. Any such redemption shall occur ten days after written notice of the redemption is provided. There are no liquidated rights.

Series D Convertible Preferred Stock- Voting- Shall be entitled to the number of votes as shall be equal to the aggregate number of shares of Common Stock into which the Series D shall be convertible. Liquidation- Upon Liquidation, the Holders shall be entitled to receive an amount equal to the Holder's pro rata share of the assets and funds of the corporation to be distributed. Conversion- The number of shares of common stock to which a Holder of Preferred Stock shall, in aggregate, equal 75% of the post conversion number of shares of Common Stock issued and outstanding. Individual shares of Series D preferred stock shall be convertible into that pro-rata number of common shares equal to .00001 x the aggregate number of shares issuable. There are no redemption rights.

3. **Describe any other material rights of common or preferred stockholders.**

NA

4. **Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.**

NA

3) **Issuance History**

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
Opening Balance Date <u>12/31/2020</u> Common: 4,874,316,008 Preferred: <u>3,355,126</u>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
02/11/2021	Issuance	461,330,466	Common	<u>.004</u>	No	<u>Union Capital LLC Yakov Borenstein</u>	Note conversion	Unrestricted	<u>4(a)1</u>
02/24/2021	Issuance	468,030,000	Common	<u>.0018</u>	No	<u>BB Winks LLC Craig Fisher</u>	Note conversion	Unrestricted	<u>4(a)1</u>
4/28/2021	Issuance	271,867,306	Common	<u>.0016</u>	Yes	<u>Union Capital LLC Yakov Borenstein</u>	Note conversion	Unrestricted	<u>4(a)1</u>
06/01/2021	Issuance	460,000,000	Common	<u>.0016</u>	Yes	<u>Bruce Lewis</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	12,523,985	Common	<u>.0016</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/23/21	Issuance	308,276,015	Common	<u>.0015</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	70,000,000	Common	<u>.0015</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	9,200,000	Common	<u>.0015</u>	Yes	<u>Gel Properties LLC Aryeh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
9/23/21	Issuance	145,370,766	Common	<u>.002</u>	Yes	<u>Lance Quartieri</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
9/20/21	Issuance	307,258,460	Common	<u>.002</u>	Yes	<u>Richard Grossfeld</u>	Pref A Conversion	Unrestricted	<u>4(a)1</u>
9/20/21	Cancellation	(22,151)	Pref A	<u>N/A</u>	N/A	<u>Richard Grossfeld</u>	Conversion to common	N/A	<u>N/A</u>
10/15/21	Cancellation	(46,052)	Pref B	<u>N/A</u>	N/A	<u>Jamie Safier</u>	Conversion to Pref A	N/A	<u>N/A</u>
10/15/21	Issuance	30,000	Pref A	<u>.002</u>	No	<u>Jamie Safier</u>	Conversion of Pref B	Unrestricted	<u>4(a)1</u>

10/26/21	Cancellation	(30,000)	Pref A	<u>N/A</u>	N/A	<u>Jamie Safier</u>	Conversion to common	N/A	<u>N/A</u>
10/26/21	Issuance	443,290,500	Common	<u>.002</u>	Yes	<u>Jamie Safier</u>	Conversion of Pref A	Unrestricted	<u>4(a)1</u>
1/13/2022	Issuance	150,035,000	Common	<u>.001</u>	Yes	<u>Walter Deal</u>	Conversion of debt	Unrestricted	<u>4(a)1</u>
5/25/2022	Issuance Cancellation	391,093,524 (24,500)	Common Pref A	<u>.002</u> <u>N/A</u>	Yes N/A	<u>David Lewis</u>	Conversion of Pref A	unrestricted	<u>4(a)1</u>
6/3/2022	Issuance Issuance	66,666 33,335	Pref D Pref A	<u>.002</u> <u>.002</u>	No No	<u>Dr. Jamalooddeen</u>	Share exchange	Restricted Restricted	<u>4(a)2</u>
6/3/2022	Issuance Issuance	33,333 16,666	Pref D Pref A	<u>.002</u> <u>.002</u>	No No	<u>Dylon DuPlooy</u>	Share exchange	Restricted Restricted	<u>4(a)2</u>
7/2/2023	Issuance Returned to treasury	418,629,601 (25,000)	Common Pref A	<u>.002</u> <u>N/A</u>	NA NA	<u>Walter Deal</u>	Conversion of Pref A	unrestricted	<u>4(a)1</u>

Shares Outstanding on Date of This Report:

Ending Balance

Ending Balance:

Date 09/30/2024

Common: 8,791,221,631

Preferred: 3,387,423

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

—	—	—	—	—	—	—	—
---	---	---	---	---	---	---	---

***Control persons for any entities in the table above must be disclosed in the table or in a footnote here.

Use the space below to provide any additional details, including footnotes to the table above:

—

4) Issuer’s Business, Products and Services

The purpose of this section is to provide a clear description of the issuer’s current operations. Ensure that these descriptions are updated on the Company’s Profile on www.OTCMarkets.com.

A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)

Protex is a Biotech Company developing a Hemp/CBD – Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes & technologies.

Under the leadership of its founders Mr. Dylon Du Plooy and Dr. Ahmed Jamalooden we partner with leading hospitals and universities globally to advance the clinical benefits and applications of cannabinoids. Mr. Du Plooy is a South African pioneer in the research, cultivation, production and distribution of cannabinoids. Dr. J manages a 5000-hectare farm in New Castle, South Africa. Dr. J manages a hemp pilot/ MOU issued by the Government of South Africa. Together the RSAMMDA founders have been at the forefront of cannabis legislation and South African cannabis legalization, which took place in September 2018. We are committed to the advancement of technology and scientific research that leads to an improved quality of life for patients around the world.

B. List any subsidiaries, parent company, or affiliated companies.

- Plandai Biotechnology
- Cannabis Biosciences, Inc.
- RSAMMD Acquisitions LLC

C. Describe the issuers’ principal products or services.

Through its prior acquisitions, Protex engages in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology.

5) Issuer’s Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The issuer utilizes space provided by its chairman at no cost. Location is 10 Hilldrop Dr. Newcastle, SA. 2940

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note/name of control person(s) if a corporate entity
<u>McCallum Trust/ Baylis Duffied</u>	<u>CEO of Plandai Biotechnology</u>	<u>17 Hanover Square, London, England</u>	0	<u>Series D Preferred</u>	0	Control person: Baylis Duffied. On May 1, 2020, Plandai Biotechnology, Inc., the entity from which Plandai Biotechnology South Africa was acquired, agreed to return and cancel all Series D shares due to breach of contract.
Steve Berman	<u>Holder of more than 5% of a class of securities</u>	New York, NY	2,675,000	Series C Preferred	100%	Voting stock only, converts to 535 million votes equal to approx. 6% Preferred holder is not a control person or affiliate and has no conversion rights
Dr. A Jamaloodeen	Chairman/President	<u>Newcastle, South Africa</u>	66,667 33,333	Pref D Pref A	67.7% 44.5%	
Dylon Du Plooy	CEO/Director	<u>Newcastle, South Africa</u>	33,333 16,667	Pref D Pref A	33.3% 22.2%	

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name:	Jonathan Leinwand
Firm:	Jonathan D. Leinwand, P.A.
Address 1:	18305 Biscayne Blvd, Suite 200
Address 2:	Aventura, FL 33180

Phone: (954) 903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: Michael Ussery, CPA
Firm: Kral Ussery, LLC
Address 1: 556 Silicon Drive, Suite 103
Address 2: Southlake, TX, 76092
Phone: 817-416-6842 ext.101
Email: MUssery@KralUssery.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Marchello Beriy
Title: Attorney
Relationship to Issuer: Attorney

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Michael Ussery
Title: CPA
Relationship to Issuer: Accountant

Describe the qualifications of the person or persons who prepared the financial statements:⁵ Mr. Ussery is a certified public accountant.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Dylon Du Plooy certify that:

1. I have reviewed this Disclosure Statement for PROTEXT MOBILITY, INC (aka Protexit Pharma, Inc.);

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/18/2024 [Date]

/S/ Dylan Du Plooy [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Dylon Du Plooy certify that:

1. I have reviewed this Disclosure Statement for PROTEXT MOBILITY, INC (aka Protext Pharma, Inc.);;;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/18/2024 [Date]

/S/ Dylan Du Plooy [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Protext Mobility, Inc.
(aka Protext Pharma, Inc.)
OTCPK: TXTM
Financial Statements
September 30, 2024
(Unaudited)

PROTEXT MOBILITY, INC.**(aka Protext Pharma, Inc.)****Balance Sheets
(Unaudited)**

	September 30, 2024	December 31, 2023
ASSETS		
Cash	\$ -	\$ -
Inventory-Genus Cannabis Sativa Seeds	55,000,000	15,000,000
Prepaid expenses	8,760	1,830
Total Current Assets	<u>55,008,760</u>	<u>15,001,830</u>
TOTAL ASSETS	<u><u>\$ 55,008,760</u></u>	<u><u>\$ 15,001,830</u></u>
LIABILITIES & EQUITY		
Current Liabilities		
Accrued Expenses	\$ 563,396	\$ 563,396
Accounts Payable	20,873	-
Related Party Line of Credit	86,932	62,413
Total Current Liabilities	<u>671,201</u>	<u>625,809</u>
Total Liabilities	<u>671,201</u>	<u>625,809</u>
Equity		
Common Stock, 10,000,000,000 shares par value \$0.00001 authorized, 8,791,221,631 issued and outstanding	87,912	87,912
Common Stock Issuable	-	-
Additional Paid-in Capital	57,767,451	17,767,451
Preferred Stock-Series A 100,000 par value \$0.001 shares authorized, 50,000 and 75,000 shares issued and outstanding, respectively	50	50
Preferred Stock-Series B 1,000,000 par value \$0.0001 shares authorized, 0 and 0 shares issued and outstanding	-	-
Preferred Stock - Series C 3,900,000 par value \$0.001 shares authorized, 2,675,000 issued and outstanding	2,675	2,675
Preferred Stock - Series D 100,000 par value \$0.001 shares authorized, 100,000 shares issued and outstanding, respectively	100	100
Retained Deficit	<u>(3,520,629)</u>	<u>(3,482,167)</u>
Total Equity	<u>54,337,559</u>	<u>14,376,021</u>
TOTAL LIABILITIES & EQUITY	<u><u>\$ 55,008,760</u></u>	<u><u>\$ 15,001,830</u></u>

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Statements of Operations
(Unaudited)

	For the Three Months ended September 30,		For the Nine Months ended September 30,	
	2024	2023	2024	2023
Expenses				
Professional Services	\$ 8,776	\$ 3,088	\$ 25,949	\$ 35,432
General and Admin	3,577	3,330	10,340	11,906
Total Expense	12,353	6,418	36,289	47,338
Net Operating Loss	(12,353)	(6,418)	(36,289)	(47,338)
Interest Expense	(790)	(505)	(2,173)	(1,045)
Net Loss	\$ (13,143)	\$ (6,923)	\$ (38,462)	\$ (48,383)

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.

Statements of Equity

(Unaudited)

	Shares Outstanding	Common Stock	Series A Preferred	Series B Preferred	Series C Preferred	Series D Preferred	Paid In Capital	Stock Issuable	Retained Earnings	Total
Balance at December, 2022	8,372,592,030	\$ 83,726	\$ 75	\$ -	\$ 2,675	\$ 100	\$ 17,771,612		\$ (3,257,895)	\$ 14,600,294
Conversion of Series A to Common Stock	418,629,601	4,186	\$ (25)				(4,161)			
Net Loss for the period									(48,383)	(48,383)
Balance at September 30, 2023	8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 17,767,451	\$ -	\$ (3,306,278)	\$ 14,551,910
Balance at December, 2023	8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 17,767,451		\$ (3,482,167)	\$ 14,376,021
Contribution of seeds by shareholder		-					40,000,000			40,000,000
Net Loss for the period									(38,462)	(38,462)
Balance at September 30, 2024	8,791,221,631	\$ 87,912	\$ 50	\$ -	\$ 2,675	\$ 100	\$ 57,767,451	\$ -	\$ (3,520,629)	\$ 54,337,559

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc)
Statements of Cash Flows
(Unaudited)

	For the Nine Months Ended	
	September 30,	
	2024	2023
Cash Used in Operations:		
Net loss	\$ (38,462)	\$ (48,384)
Non-cash Adjustments to operating accounts		
Change in accrued expenses and prepaids	(6,930)	5,421
Change in accounts payable	20,873	
Net cash used in operating activities	(24,519)	(42,963)
Cash Provided from Financing Activities		
Capital contributions		
Related Party Line of Credit	24,519	42,963
Working capital loan		-
Net Cash Provided by Financing Activities	24,519	42,963
Net Change in Cash Flow	-	-
Cash at beginning of period	-	-
Cash at end of period	\$ -	\$ -
Supplemental Cash Flow Information:		
Cash Paid for -		
Interest	\$ -	\$ -
Taxes	\$ -	\$ -

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Notes to Consolidated Financial Statements
September 30, 2024

NOTE 1 - DESCRIPTION OF BUSINESS AND GOING CONCERN

Description of Business

ProText Mobility Inc. (the “Company”) was incorporated in the State of Delaware on September 5, 2001 under the name SearchHelp, Inc. and completed its initial public offering on July 23, 2003. During the fiscal year ended December 31, 2008, the Company acquired 100% of the stock of EchoMetrix, Inc, which then became a wholly owned subsidiary, and in May of 2009 the Company filed a Certificate of Ownership and Merger with the State of Delaware pursuant to which EchoMetrix was merged with and into the Company, and the Company's corporate name was changed to EchoMetrix, Inc. In December 2010, the Company filed a Certificate of Ownership and Merger with the state of Delaware pursuant to which the Company's then wholly owned subsidiary, ProText Mobility, Inc., was merged with and into the Company, and the Company's corporate name was changed to Protext Mobility, Inc.

On December 31, 2016, the Company acquired Plandaí Biotechnology South Africa (Pty) Ltd. (Plandaí), a South African company headquartered in the Mpumalanga province of South Africa through a share exchange agreement, and changed the corporate name to Protext Pharma, Inc. Plandaí was formed in 2014 and focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients. Under the terms of acquisition, the Company issued 100,000 shares of Series D Preferred Stock in exchange for all of the issued and outstanding shares of Plandaí. The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters. On May 1, 2020, Plandaí Biotechnology, Inc., the entity from which Plandaí Biotechnology South Africa was acquired, agreed to return and cancel all Series D shares due to breach of contract.

As a result of the acquisition of Plandaí, the former shareholders of Plandaí became the control entity, having voting and conversion rights equal to 75%. Plandaí elected to become the successor issuer to the Company for accounting and reporting purposes. Accordingly, the accompanying financial statements represent the results of operations of Plandaí Biotechnology South Africa exclusive of those of ProText Mobility. The balance sheet contains the consolidated assets and liabilities of both entities for all periods presented while the retained deficit is that of Plandaí exclusively. The shares of common stock of ProText Mobility outstanding as of the acquisition date are shown as issued as of the acquisition date while the shares issued to acquire Plandaí are shown as outstanding for all periods presented.

On March 14, 2017, the Company acquired 100% of the capital stock of Cannabis Biosciences, Inc., in exchange for 50,000,000 shares of the Company's restricted common stock. Cannabis Biosciences is engaged in the development of a non-psychoactive, full-profile cannabis extract using the Phytofare® technology for pharmaceutical applications. The operations of Cannabis Biosciences from the date of the acquisition forward have been consolidated in these financial statements.

On June 3, 2022, the Company acquired 100% of the capital stock of RSAMMD Acquisition LLC, a Delaware corporation (“RSAMMDA”), in exchange for 100,000 shares of Series D Preferred Stock and 50,000 shares of Series A Preferred Stock (the “Acquisition Agreement”). The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters. The Series A Preferred issued have conversion rights equal to 10% of the post-conversion issued and outstanding shares of common stock and

voting rights equivalent to the total shares issuable on conversion. This transaction resulted in a change of control with the shareholders of RSAMMDA controlling over 85% of the total voting stock of the Company.

The sole shareholders of RSAMMDA were Mr. Dylan Du Plooy and Dr. Ahmed Jamalooden who also served as the chief financial officer and chief executive officers, respectively, of RSAMMDA. Both assumed similar roles at the Company. RSAMMDA had no operations or assets prior to the acquisition. The acquisition of RSAMMDA was accounted for as a capital transaction. The Company recorded the issuance of the Series D Preferred Stock and the Series A Preferred Stock at the par value of the with an equal amount recorded in APIC.

As a condition of the Acquisition Agreement, all accrued and unpaid expenses and loans, which primarily consisted of accrued and unpaid consulting fees to the Company's prior chief executive officer, were cancelled and forgiven. The cancelled obligations were approximately \$708,677.

RSAMMDA was formed on January 14 2022 to facilitate a working relationship to commercialize the Company's proprietary live plant extraction system. Management is developing a sustainable business to leverage the same, including distribution.

Going Concern

The Company's consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company generated a net loss of \$38,462 for the nine months ended September 30, 2024 and a net loss of \$54,272 for the year ended December 31, 2023.

As of September 30, 2024, the Company had stockholders' equity of \$54,337,559 and total liabilities of \$671,201. The Company had working capital of \$54,437,864 The Company's primary asset is comprised of Genus Cannabis Sativa seeds donated by the Company's major shareholder. The Company has recorded no sales during any of the periods presented.

These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for the twelve months following the issuance of its financial statements for the nine months ended September 30, 2024. The Company's ability to continue as a going concern is dependent upon its ability to utilize the resources in place to generate future profitable operations and to obtain the necessary financing to meet its debt obligations and repay its liabilities arising from business operations when they come due. Management believes that with the recent acquisition of RSAMMDA and the change in management, the Company will be able to leverage the expertise and relationships of Management to develop its proprietary live plant extraction technology as well as its distribution network.

Although the Company believes that it will be successful, these conditions continue to raise substantial doubt regarding the Company's ability to continue as a going concern.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States.

Use of Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. We regularly evaluate our estimates and assumptions related to the useful life and recoverability of long-lived assets, stock-based compensation and deferred income tax asset valuation allowances. We base our estimates and assumptions on current facts, historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and

liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by us may differ materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual results, our future results of operations will be affected.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired, to be cash equivalents.

Income Taxes

The Company accounts for income taxes under the provisions issued by the FASB which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company computes tax asset benefits for net operating losses carried forward. The potential benefit of net operating losses has not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

Fair Value of Financial Instruments

Pursuant to ASC No. 820, "Fair Value Measurements and Disclosures", the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of June 30, 2024 and December 30, 2023. The Company does not have any financial instruments as of those dates. The Company considers the carrying value of such amounts in the financial statements to approximate their fair value due to the short-term nature of these financial instruments.

The Company adopted ASC No. 820-10 (ASC 820-10), Fair Value Measurements. ASC 820-10 relates to financial assets and financial liabilities. ASC 820-10 defines fair value, establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (GAAP), and expands disclosures about fair value measurements. The provisions of this standard apply to other accounting pronouncements that require or permit fair value measurements and are to be applied prospectively with limited exceptions.

ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This standard is now the single source in GAAP for the definition of fair value, except for the fair value of leased property as defined in SFAS 13. ASC 820-10 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions, about market participant assumptions, that are developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
- Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management's own assumptions about the assumptions that market participants would use in pricing

the asset or liability. (The unobservable inputs are developed based on the best information available in the circumstances and July include the Company's own data.)

There are no assets and liabilities measured at fair value on a non-recurring basis as of September 30, 2024 and December 31, 2023.

NOTE 3 - EQUITY

Common Stock

The Company has authorized 10 billion shares of common stock, par value \$0.00001, of which 8,791,221,631 shares were issued and outstanding as of September 30, 2024 and December 31, 2023.

Series A Preferred

The Company has 100,000 shares of Series A Preferred stock, par value \$0.001, authorized of which 50,000 shares were issued and outstanding on September 30, 2024 and December 31, 2023. The Series A Preferred has conversion rights equal to 20% of the post-conversion issued and outstanding shares of common stock and voting rights equivalent to the total shares issuable on conversion.

Series B Preferred

As of September 30, 2024 and December 31, 2023, there were no shares of Series B Preferred issued and outstanding. The Series B Preferred has voting rights equal to two votes per share on all shareholder matters and has a preference on dividend payments.

Series C Preferred

The Company has authorized 3,900,000 shares of Series C Preferred stock, par value \$0.001. As of September 30, 2024 and December 31, 2023 there were 2,675,000 Series C shares outstanding. The Series C have voting rights equal to 200 votes per share on all shareholder matters.

Series D Preferred

On June 3, 2022, the Company issued 100,000 shares of Series D Preferred stock as partial consideration for the Acquisition Agreement. The Series D Preferred stock has conversion rights equal to 75% of the post-conversion common stock and voting rights equivalent to the number of shares issuable on conversion.

NOTE 4 RELATED PARTY TRANSACTIONS

During 2022, Company's President and Chairman of the Board paid certain bills including registration fees and legal fees on behalf of the Company. Such payments aggregated approximately \$8,644. On December 31, 2022, Company's President and Chairman of the Board offered and the board of directors agreed to extend the Company a line of credit in the amount of \$100,000 with interest of 4% per annum. The \$8,644 payable to Company's President and Chairman of the Board was converted into the line of credit. During the three month periods ended September 30, 2024 and 2023, the Company's President and Chairman of the Board made payments on behalf of the Company in the amount of \$9,893 and \$1,500 respectively. During the nine month periods ended September 30, 2024 and 2023, the Company's President and Chairman of the Board made payments on behalf of the Company in the amount of \$22,346 and \$42,457, respectively. The Balance of the line of credit as of September 30, 2024 and December 31, 2023 was \$86,933 and \$62,413, respectively. During the three month periods ended September 30, 2024 and 2023, the Company recognized \$789 and \$505 in interest expense relating to the line of credit. During the nine month periods ended September 30, 2024 and 2023, the Company recognized \$2,173 and \$1,045 in interest expense relating to the line of credit.

The Company's CEO, and the Company's President and Chairman of the Board each earn a salary of \$1.00 per year.

Dr. A Jamalooden (chairman and president) has implemented, with consent of additional shareholders, an open ended, discretionary, stock purchase program. During the quarter ended September 30, 2024, Dr. A Jamalooden purchased 5,666,266 shares on the open market under the program, in his own name.

Inventory

On December 15, 2022, the Company's President and Chairman of the Board contributed approximately 15,000,000 Genus Cannabis Sativa Seeds (the "Seeds") to the Company as an equity contribution (the "Contribution"). On May 15, 2024, the Company's President and Chairman of the Board made an additional Contribution of approximately 40,000,000 Seeds.

The Contributions were recorded as Genus Cannabis Sativa Seed inventory at historical cost to the Company's President and Chairman of the Board of approximately \$1 per seed (R17.0301 per seed at December 15, 2022 and 18.3996 per seed at May 15, 2024) for a total of \$55,000,000. The Company estimates the fair value of the seeds is substantially in excess of the recorded value of \$55,000,000. The spot price for similar seeds had a retail market price in the range of 15-25 euro per seed, excluding, but not limited to shipping, customs duty (if applicable), VAT, clearing agent fees, in-land haulage and other variable costs.

In October, 2023, the Company entered into a seed multiplication agreement with a related party ("Grower") to plant, germinate and process the Company's existing 15,000,000 seed inventory. In exchange, the upon harvesting, the Grower will deliver 60,000,000 new seeds to the Company.

On April 1, 2024, 15,000,000 of the Seeds from the December 2022 Contribution were delivered to Grower to plant and germinate. During the planting cycle rotation, the seeds were successfully germinated, harvested and processed. On June 28, 2024, the Grower delivered to the company approximately 60,000,000 new Seeds. No consideration was exchanged in the multiplication agreement and the 60,000,000 seeds received were recorded at the historical cost of the original contribution.

As of September 30, 2024, the company has 100,000,000 seeds in inventory.

The agreement is subject to customary representations and warranties, including specifications of the new seed quality.

Supply Agreement

As part of the Company's general business, it plans to fulfill orders and ship products to end customers around the world, including biomass derived from hemp, raw or processed CBD, and/or finished health and wellness products containing CBD (derived from Genus Cannabis Sativa). The end products are anticipated to be shipped as partial shipments (LCL) to the end customer in compliance with the rules and regulations of each jurisdiction involved by the responsible parties. Such that the Company can fulfill orders, the Company entered into a Supply Agreement with its President and Chairman of the Board in his capacity as an independent fourth generation farmer who controls, among other things, a 5,000 hectare farm in the jurisdiction of New Castle, South Africa. The Company's President and Chairman of the Board in his individual capacity as an independent farmer controls certain permits related to activities such as cultivation, import/export of various agricultural products including but not limited to genus cannabis sativa. The Company does not plant, own or control any farm, and has no permit.

The Company's President and Chairman of the Board, in his capacity as an independent farmer and a team, managed by the Company's CEO- Dylon Du Plooy, in his individual capacity, are responsible for planting hemp crops derived from Genus Cannabis Sativa seeds at a farm controlled by the Company's President and Chairman of the Board. In the future, the Company's President and Chairman of the Board may provide the Company with access to, and/or the Company may receive benefit from, permits controlled by the Chairman. There are no guarantees that this will occur. Furthermore, the Company does not need such access, specifically to permits held by its President and Chairman of the Board in his individual capacity as a private citizen and independent farmer within jurisdiction of South Africa, to carry out its business endeavors such as fulfilling and shipping product to end customers.

NOTE 5 ACCRUED EXPENSES

On November 11, 2019, Joseph Canouse obtained a default judgment against the Company totaling \$563,396.72. On April 8, 2022, the Company filed in the District Court, Southern District of New York for the United States of America a Motion to Set Aside the Judgment, which was denied and the Company has filed for review the United States Appellate Courts overseeing the Southern District of New York. In addition, the Company has filed against Mr. Canouse and the Company's former CEO Steve Berman (who assigned claims to Mr. Canouse that are the basis of the Judgment). The Company filed the action against Mr. Berman and Mr. Canouse in the 11th Judicial District in and for Miami-Dade County, Florida on or about April 8, 2022. The case against Mr. Canouse and Mr. Berman was dismissed without prejudice on or about October 10, 2023. The Company's estimate of the loss associated with the judgment is \$563,396 and is recorded as accrued expenses.

NOTE 6 - SUBSEQUENT EVENTS

The Company reviewed transactions through November 18, 2024, and noted the following material events.

Effective October 29, 2024, the Company's principal shareholder acquired an additional 112,500,000 common shares as part of a private sale.